A statistical methodology for drug-drug interaction surveillance

Statistics in Medicine

Volumn 27, Issue 16, 2008, Pages 3057-3070

  Norén, G Niklas ^a   Sundberg, Rolf ^b   Bate, Andrew ^a,c   Edwards, I Ralph ^a  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Adverse drug reaction; Exploratory analysis; Interaction; Shrinkage; Surveillance

Indexed keywords

AMOXICILLIN; CARBOPLATIN; CEFACLOR; CELECOXIB; CERIVASTATIN; CISAPRIDE; CISPLATIN; CITALOPRAM; CLARITHROMYCIN; DIGOXIN; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIURETIC AGENT; DONEPEZIL; FUROSEMIDE; GEMFIBROZIL; HAEMOPHILUS VACCINE; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; OXYCODONE; QUETIAPINE; RABEPRAZOLE; RISPERIDONE; TERFENADINE; UNINDEXED DRUG; VALPROIC ACID; VANCOMYCIN;

ARTICLE; BLEEDING DISORDER; CARDIOTOXICITY; DATA ANALYSIS; DATA BASE; DEPRESSION; DISEASE EXACERBATION; DRUG ABUSE PATTERN; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; EPIDERMOLYSIS; EXPLORATORY RESEARCH; HEART BLOCK; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOTONIC HYPORESPONSIVE EPISODE; LOGISTIC REGRESSION ANALYSIS; MEDICATION ERROR; NEUROLOGIC DISEASE; POPULATION MODEL; POSTMARKETING SURVEILLANCE; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; STATISTICAL ANALYSIS; SUICIDE ATTEMPT; TOOTH DISEASE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTRACEPTIVES, ORAL; DIURETICS; DRUG INTERACTIONS; DRUG THERAPY; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MODELS, STATISTICAL; PRODUCT SURVEILLANCE, POSTMARKETING; TERFENADINE;

EID: 48049111575     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3247     Document Type: Article

References (18)

1. Rawlins MD. Spontaneous reporting of adverse drug reactions. II: Uses. British Journal of Clinical Pharmacology 1988; 26(1):7-11.
2. Edwards IR, Wiholm BE, Lindquist M, Napke E. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336(8708):156-158.
3. Norén GN, Orre R, Bate A, Edwards IR. Duplicate detection in adverse drug reaction surveillance. Data Mining and Knowledge Discovery 2007; 14(3):305-328.
4. Stephens MDB. Ethical issues in drug safety. In Stephens' Detection of New Adverse Drug Reactions, Talbott J, Waller P (eds). Wiley: New York, 2004; 591-648.
5. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, De Freitas RM. A Bayesian neural network method for adverse drug reaction signal generation. European Journal for Clinical Pharmacology 1998; 54: 315-321.
6. Pirmohamed M, Orme ML. Drug interactions of clinical importance. In Davies's Textbook of Adverse Drug Reactions, Davies DM, Ferner RE, de Glanville H (eds). Chapman & Hall: London, 1998; 888-912.
7. Rothman KJ, Greenland S, Walker AM. Concepts of interaction. American Journal of Epidemiology 1980; 112(4):467-470.
8. van Puijenbrock EP, Egberts ACG, Meyboom REB, Leulkens HGM. Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. British Journal of Clinical Pharmacology 1999; 47:689-693.
9. van Puijenbroek EP, Egberts ACG, Heerdink ER, Leufkens HGM. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. European Journal of Clinical Pharmacology 2000; 56:733-738.
10. DuMouchel W, Pregibon D. Empirical Bayes screening for multi-item associations. Proceedings of the Seventh ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, San Francisco, California, 2001; 67-76.
11. Norén GN, Bate A, Orre R, Edwards IR. Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events. Statistics in Medicine 2006; 25(21):3740-3757.
12. Almenoff JS, DuMouchel W, Kindman LA, Yang X, Fram D. Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post-marketing setting. Pharmacoepidemiology and Drug Safety 2003; 12(6):517-521.
13. Yang X, Fram DM. Using disproportional analysis as a tool to explore severe drug-drug interactions in AERS database. Pharmacoepidemiology and Drug Safety 2004; 13(1):S247.
14. van Wattum PJ. Letter to the editor: Valproic acid and risperidone. Journal of the American Academy of Child and Adolescent Psychiatry 2000; 40(8):866-867.
15. Skrondal A. Interaction as departure from additivity in case-control studies: a cautionary note. American Journal of Epidemiology 2003; 158(3):251-258.
16. Evans SJW. Statistics: analysis and presentation of safety data. In Stephens' Detection of New Adverse Drug Reactions, Talbott J, Waller P (eds). Wiley: New York, 2004; 301-328.
17. Ståhl M, Lindquist M, Edwards IR, Brown EG. Introducing triage logic as a new strategy for the detection of signals in the WHO drug monitoring database. Drug Safety 2004; 13(6):355-363.
18. Strandell J, Kiuru A, Lindquist M. Linking spontaneous reports with pharmacogenetics. Basic and Clinical Pharmacology and Toxicology 2005; 97(S1):106.